(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of 0.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Puma Biotechnology's revenue in 2025 is $232,709,000.On average, 2 Wall Street analysts forecast PBYI's revenue for 2025 to be $10,739,697,801, with the lowest PBYI revenue forecast at $10,737,712,278, and the highest PBYI revenue forecast at $10,741,683,325. On average, 2 Wall Street analysts forecast PBYI's revenue for 2026 to be $11,699,698,520, with the lowest PBYI revenue forecast at $11,694,734,711, and the highest PBYI revenue forecast at $11,704,662,329.
In 2027, PBYI is forecast to generate $12,337,051,634 in revenue, with the lowest revenue forecast at $12,334,073,349 and the highest revenue forecast at $12,340,029,920.